Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial.
暂无分享,去创建一个
David D. Shin | I. Piña | C. O'connor | M. Gheorghiade | J. Butler | G. Fonarow | J. Rogers | T. DeMarco | G. Francis | W. G. Stough | J. Hare | A. Hellkamp | D. Pauly | T. Disalvo | W. Cotts | J. Rossi
[1] J. Cohn,et al. Neurohumoral control mechanisms in congestive heart failure. , 1981, American heart journal.
[2] T. Berl,et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. , 2006, The New England journal of medicine.
[3] G. Fonarow,et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. , 2007, European heart journal.
[4] D. DeMets,et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). , 2005, Journal of cardiac failure.
[5] David D. Shin,et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial , 2007, Acute cardiac care.
[6] Christopher M O'Connor,et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. , 2004, JAMA.
[7] V. Dzau. Renal and circulatory mechanisms in congestive heart failure. , 1987, Kidney international.
[8] M. Gheorghiade,et al. Vasopressin V2-Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure: Results From a Double-Blind, Randomized Trial , 2003, Circulation.
[9] E. Braunwald,et al. CATECHOLAMINE EXCRETION AND CARDIAC STORES OF NOREPINEPHRINE IN CONGESTIVE HEART FAILURE. , 1965, The American journal of medicine.
[10] R. Califf,et al. Lower Serum Sodium Is Associated With Increased Short-Term Mortality in Hospitalized Patients With Worsening Heart Failure: Results From the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Study , 2005, Circulation.
[11] T. Berl,et al. Osmotic and nonosmotic control of vasopressin release. , 1979, The American journal of physiology.
[12] N. Hollenberg,et al. Hyponatremia in congestive heart failure: implications for neurohumoral activation and responses to orthostasis. , 1984, The Journal of clinical endocrinology and metabolism.
[13] W. Abraham,et al. Hormones and hemodynamics in heart failure. , 1999, The New England journal of medicine.
[14] M. Gheorghiade,et al. Vasopressin V 2-Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure Results From a Double-Blind , Randomized Trial , 2003 .
[15] William T. Abraham,et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness , 2005 .
[16] W. Frishman,et al. Systolic Blood Pressure at Admission, Clinical Characteristics, and Outcomes in Patients Hospitalized With Acute Heart Failure , 2007 .
[17] V. Hasselblad,et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. , 2004, Journal of the American College of Cardiology.
[18] A. Greenberg,et al. Diuretic complications. , 2000, The American journal of the medical sciences.
[19] V. Hasselblad,et al. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE): design and rationale. , 2001, American heart journal.
[20] William T. Abraham,et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure. Classification and regression tree analysis , 2005 .
[21] K. Swedberg,et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.
[22] L. Tavazzi,et al. Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry). , 2002, American heart journal.
[23] J. Cohn,et al. Hyponatraemia as a marker for high renin heart failure. , 1982, British heart journal.
[24] K. Swedberg,et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. , 2007, JAMA.
[25] M. Packer,et al. Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia. , 1984, The New England journal of medicine.
[26] Monica R. Shah,et al. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness The ESCAPE Trial , 2005 .
[27] N. Hollenberg,et al. Relation of the Renin‐Angiotensin-Aldosterone System to Clinical State in Congestive Heart Failure , 1981, Circulation.